Unknown PHASE1 INTERVENTIONAL 2-arm NCT03235167

Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

Sponsor: Dalian University

Interventions CpG DNA Placebo - Concentrate transcatheter arterial chemoembolization

Updated 7 times since 2017 Last updated: Sep 14, 2017 Started: Oct 31, 2017 Primary completion: Oct 31, 2022 Completion: Oct 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hepatocellular Carcinoma and is currently ongoing. Dalian University leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Not Yet Recruiting PHASE1
Jun 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

▶ Show 2 earlier versions

Oct 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1
Sep 2017 — Oct 2017 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dalian University

Data source: Dalian University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.